`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`PFIZER, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner,
`____________
`
`Case IPR2017-01489
`Patent 6,407,213 B2
`____________
`
`DECLARATION OF CHRISTOPHER J. CITRO IN SUPPORT OF
`PETITIONER’S MOTION FOR THE PRO HAC VICE ADMISSION
`
`
`
`PFIZER EX. 1692
`Pfizer v. Genentech
`IPR2017-01489
`
`
`
`Declaration of Christopher J. Citro in Support of
`Petitioner’s Motion for the Pro Hac Vice Admission of Christopher J. Citro
`
`I, Christopher J. Citro, do hereby declare:
`
`1.
`
`I am an Associate at the law firm Kirkland & Ellis LLP (“Kirkland”).
`
`Lead counsel in the inter partes review proceeding is Amanda Hollis, a Partner at
`
`Kirkland, who is registered to practice before the PTO and holds Registration No.
`
`55,629. Backup counsel are: (1) Stefan Miller, a Partner at Kirkland, who is
`
`registered to practice before the PTO and holds Registration No. 57,623; and (2)
`
`Karen Younkins, an Associate at Kirkland, who is registered to practice before the
`
`PTO and holds Registration No. 67,554. With respect to the proceeding, I will work
`
`closely with Ms. Hollis, Mr. Miller, and Ms. Younkins.
`
`2.
`
`I hold a Bachelor of Science degree in Chemistry and a Bachelor of
`
`Arts degree in Political Science from American University and a Juris Doctor degree
`
`from George Washington University Law School.
`
`3.
`
`I have approximately one year of experience as a litigation attorney
`
`specializing in patent litigation and representing clients in patent litigation matters
`
`in various United States District Courts. My experience includes several matters in
`
`the life sciences and pharmaceuticals arts. I have particular experience relevant to
`
`the technological and legal matters at issue in this proceeding, including matters
`
`concerning monoclonal antibody therapies and methods of preparing antibodies,
`
`including representing Pfizer, Inc. (“Petitioner”) in a number of related matters. I
`
`am, therefore, an experienced patent litigation attorney with particular expertise that
`
`2
`
`PFIZER EX. 1692
`Pfizer v. Genentech
`IPR2017-01489
`
`
`
`Declaration of Christopher J. Citro in Support of
`Petitioner’s Motion for the Pro Hac Vice Admission of Christopher J. Citro
`
`is pertinent to the proceeding. Petitioner desires, and has a need to be represented
`
`in certain aspects of this proceeding by an experienced patent litigation attorney who
`
`has particular expertise that is relevant to the issues involved.
`
`4.
`
`I am very familiar with U.S. Patent No. 6,407,213, as well as the legal
`
`subject matter, technical subject matter, and prior art discussed in the Request for
`
`Inter Partes Review. I have personally reviewed the patent at issue, as well as the
`
`prosecution history, submissions filed in this proceeding, and accompanying
`
`declarations and exhibits. I have been and continue to be actively involved with
`
`strategic, factual, and technical aspects of this matter.
`
`5.
`
`I am a member in good standing of the Bars of the State of New York
`
`and the District of Columbia.
`
`6.
`
`I have never been suspended or disbarred from practice before any court
`
`or administrative body.
`
`7.
`
`I have never had a court or administrative body deny my application for
`
`admission to practice.
`
`8.
`
`I have never been sanctioned or cited for contempt by any court or
`
`administrative body.
`
`9.
`
`I have read and will comply with the Office Patent Trial Practice Guide
`
`and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`
`
`3
`
`PFIZER EX. 1692
`Pfizer v. Genentech
`IPR2017-01489
`
`
`
`Declaration of Christopher J. Citro in Support of
`Petitioner’s Motion for the Pro Hac Vice Admission of Christopher J. Citro
`
`
`10.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Code of Professional Responsibility set forth in 37 C.F.R. §§ 11.101 et. seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`11.
`
`I have been admitted pro hac vice as counsel in the following
`
`proceedings before the United States Patent and Trademark Office:
`
`• IPR2017-00804 and IPR2017-00805 as counsel for Hospira, Inc.
`
`concerning dosages for treatment with anti-ErbB2 antibodies.
`
`• IPR2017-00737 as counsel for Hospira, Inc. concerning treatment
`
`with anti-ErbB2 antibodies.
`
`12.
`
`I declare that all statements made herein of my own knowledge are true
`
`and that all statements made on information and belief are believed to be true, and
`
`further that these statements were made with the knowledge that willful, false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code.
`
`Date: November 2, 2017
`
`Respectfully submitted,
`
`By: /s/Christopher J. Citro
`Christopher J. Citro
`Kirkland & Ellis LLP
`601 Lexington Avenue
`New York, NY 10022
`Telephone: (212) 909-3141
`Facsimile: (212) 446-4900
`christopher.citro@kirkland.com
`
`4
`
`
`
`
`
`
`
`PFIZER EX. 1692
`Pfizer v. Genentech
`IPR2017-01489
`
`